The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
13
08
2019
received:
08
03
2019
accepted:
27
09
2019
pubmed:
15
11
2019
medline:
6
7
2021
entrez:
15
11
2019
Statut:
ppublish
Résumé
Cancer-induced bone pain remains inadequately controlled, and current standard of care analgesics is accompanied by several side effects. Nociceptin/orphanin FQ peptide (NOP) receptor agonists have demonstrated broad analgesic properties in rodent neuropathic and inflammatory pain models. Here, we investigate the analgesic potential of NOP receptor activation in a rodent cancer-induced bone pain model. Model validation by intratibial inoculation in male Sprague Dawley rats was performed with varying MRMT-1/Luc2 cell quantities (0.5-1.5 × 10 Inoculation with 1.5 × 10 Nociceptin and Ro65-6570 selectively and dose-dependently reversed cancer-induced bone pain-like behaviour. The NOP receptor system may be a potential target for cancer-induced bone pain treatment. This article is part of a themed issue on The molecular pharmacology of bone and cancer-elated bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.
Sections du résumé
BACKGROUND AND PURPOSE
Cancer-induced bone pain remains inadequately controlled, and current standard of care analgesics is accompanied by several side effects. Nociceptin/orphanin FQ peptide (NOP) receptor agonists have demonstrated broad analgesic properties in rodent neuropathic and inflammatory pain models. Here, we investigate the analgesic potential of NOP receptor activation in a rodent cancer-induced bone pain model.
EXPERIMENTAL APPROACH
Model validation by intratibial inoculation in male Sprague Dawley rats was performed with varying MRMT-1/Luc2 cell quantities (0.5-1.5 × 10
KEY RESULTS
Inoculation with 1.5 × 10
CONCLUSION AND IMPLICATIONS
Nociceptin and Ro65-6570 selectively and dose-dependently reversed cancer-induced bone pain-like behaviour. The NOP receptor system may be a potential target for cancer-induced bone pain treatment.
LINKED ARTICLES
This article is part of a themed issue on The molecular pharmacology of bone and cancer-elated bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.
Identifiants
pubmed: 31724155
doi: 10.1111/bph.14899
pmc: PMC8246843
doi:
Substances chimiques
Opioid Peptides
0
Receptors, Opioid
0
Nociceptin Receptor
0
Oprl protein, rat
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1995-2007Subventions
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 814244
Organisme : Marie Sklodowska-Curie
ID : 642720
Informations de copyright
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Pain Physician. 2017 Feb;20(2S):S93-S109
pubmed: 28226333
Cancers (Basel). 2011 Dec 16;3(4):4281-93
pubmed: 24213139
Pain. 1998 Jun;76(3):385-393
pubmed: 9718257
Peptides. 2000 Jul;21(7):949-60
pubmed: 10998528
Biol Pharm Bull. 2001 Aug;24(8):902-5
pubmed: 11510482
Neurosci Lett. 2013 May 10;542:118-22
pubmed: 23545207
Pain. 2018 Apr;159(4):684-698
pubmed: 29300279
J Mol Neurosci. 2018 Sep;66(1):10-16
pubmed: 30074175
Pain Pract. 2017 Nov;17(8):1032-1041
pubmed: 28112482
Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592
pubmed: 28683172
Drug Des Devel Ther. 2015 Aug 18;9:4239-45
pubmed: 26316696
Nature. 1995 Oct 12;377(6549):532-5
pubmed: 7566152
F1000Res. 2015 Jul 31;4:445
pubmed: 26834983
Neuroscience. 2018 Aug 1;384:111-119
pubmed: 29852245
Schmerz. 2009 Apr;23(2):180-6
pubmed: 19066981
J Pharmacol Exp Ther. 2011 Nov;339(2):537-44
pubmed: 21816956
Br J Pharmacol. 2006 Aug;148(7):938-46
pubmed: 16783411
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Brain Res. 2006 Mar 17;1078(1):212-8
pubmed: 16563360
Cancer Lett. 1998 May 15;127(1-2):129-34
pubmed: 9619868
Br J Pharmacol. 2018 Jul;175(13):2662-2675
pubmed: 29582417
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Neuroscience. 2015 Apr 16;291:93-105
pubmed: 25686524
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
J Orthop Res. 2006 Jun;24(6):1193-9
pubmed: 16649179
Pain. 2004 Jul;110(1-2):236-45
pubmed: 15275773
J Histochem Cytochem. 2001 Nov;49(11):1387-95
pubmed: 11668192
Br J Pharmacol. 2021 May;178(9):1995-2007
pubmed: 31724155
J Neurosci Res. 2007 May 15;85(7):1478-88
pubmed: 17387690
J Pharmacol Exp Ther. 2014 Jun;349(3):535-48
pubmed: 24713140
Ther Clin Risk Manag. 2008 Aug;4(4):777-87
pubmed: 19209260
Eur J Pharmacol. 2000 Sep 15;404(1-2):153-9
pubmed: 10980274
Am J Physiol Regul Integr Comp Physiol. 2003 Jun;284(6):R1477-85
pubmed: 12573980
J Clin Oncol. 2014 Dec 20;32(36):4149-54
pubmed: 25403222
Br J Pharmacol. 2014 Aug;171(16):3777-800
pubmed: 24762001
Eur J Pharmacol. 1999 Jul 9;376(3):R1-3
pubmed: 10448896
Pain. 2002 Mar;96(1-2):129-40
pubmed: 11932069
Peptides. 2011 Jul;32(7):1530-5
pubmed: 21672568
Eur J Pharmacol. 2010 Oct 25;645(1-3):119-26
pubmed: 20674566
Science. 1995 Nov 3;270(5237):792-4
pubmed: 7481766
J Neurosci. 1999 Dec 15;19(24):10886-97
pubmed: 10594070
Br J Anaesth. 1999 Sep;83(3):470-1
pubmed: 10655922
Eur J Pharmacol. 2015 May 5;754:61-5
pubmed: 25697471
J Neuroinflammation. 2016 Jun 07;13(1):141
pubmed: 27267059
Neuropharmacology. 2008 Mar;54(3):564-8
pubmed: 18082848
Curr Opin Neurobiol. 2014 Dec;29:159-64
pubmed: 25064178
Brain Res. 2003 Oct 24;988(1-2):189-92
pubmed: 14519541
Neuroreport. 1997 Jan 20;8(2):497-500
pubmed: 9080436
Eur J Cancer. 2008 May;44(8):1083-90
pubmed: 18439817
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Bioorg Med Chem Lett. 2000 Apr 17;10(8):831-4
pubmed: 10782696
Curr Pain Headache Rep. 2006 Aug;10(4):288-92
pubmed: 16834944
Drug Alcohol Depend. 2011 Apr 1;114(2-3):253-6
pubmed: 21095077
Pain. 2001 Sep;93(3):247-257
pubmed: 11514084
Yonsei Med J. 2013 May 1;54(3):763-71
pubmed: 23549827
Expert Opin Pharmacother. 2015 Jan;16(1):5-15
pubmed: 25479712
Sci Rep. 2017 Jul 6;7(1):4792
pubmed: 28684771
West J Emerg Med. 2018 May;19(3):557-558
pubmed: 29760855
ACS Chem Neurosci. 2013 Feb 20;4(2):214-24
pubmed: 23421672
Pain. 2015 Jun;156(6):1124-1144
pubmed: 25775359
Eur J Pharmacol. 2018 May 15;827:41-48
pubmed: 29524385
J Pharmacol Toxicol Methods. 1994 Apr;31(2):79-83
pubmed: 8032098